WO2002044217A3 - Humanised antibodies and uses thereof - Google Patents

Humanised antibodies and uses thereof Download PDF

Info

Publication number
WO2002044217A3
WO2002044217A3 PCT/GB2001/005260 GB0105260W WO0244217A3 WO 2002044217 A3 WO2002044217 A3 WO 2002044217A3 GB 0105260 W GB0105260 W GB 0105260W WO 0244217 A3 WO0244217 A3 WO 0244217A3
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
sequence
backmutated
variable region
substantially homologous
Prior art date
Application number
PCT/GB2001/005260
Other languages
French (fr)
Other versions
WO2002044217A2 (en
Inventor
Benny Kwan Ching Lo
Charles Anthony Laughton
Michael Rawlings Di Price
Original Assignee
Univ Nottingham
Crc Technology Ltd
Benny Kwan Ching Lo
Charles Anthony Laughton
Price Frances Margaret Lf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nottingham, Crc Technology Ltd, Benny Kwan Ching Lo, Charles Anthony Laughton, Price Frances Margaret Lf filed Critical Univ Nottingham
Priority to US10/433,349 priority Critical patent/US20050033030A1/en
Priority to AU2002220843A priority patent/AU2002220843A1/en
Priority to EP01998567A priority patent/EP1339752A2/en
Publication of WO2002044217A2 publication Critical patent/WO2002044217A2/en
Publication of WO2002044217A3 publication Critical patent/WO2002044217A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/106—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from kidney or bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Abstract

A humanised antibody capable of binding to the MUC1 mucin antigen comprises a light chain and a heavy chain. The variable region of the light chain (VL) comprising an amino acid sequence which is substantially homologous with the sequence of Fig.1A and the variable region of the heavy chain (VH) comprising an amino acid sequence which is substantially homologous with the sequence of Fig. 1B. The amino acid residue at position 46 on VL is backmutated to arginine, and the amino acid residue at position 47 on VH is backmutated to leucine. The humanised antibody has use in the diagnosis and/or treatment of cancer.
PCT/GB2001/005260 2000-12-01 2001-11-29 Humanised antibodies and uses thereof WO2002044217A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/433,349 US20050033030A1 (en) 2000-12-01 2001-11-29 Humanised antibodies and uses thereof
AU2002220843A AU2002220843A1 (en) 2000-12-01 2001-11-29 Humanised antibodies and uses thereof
EP01998567A EP1339752A2 (en) 2000-12-01 2001-11-29 Humanised antibodies and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0029360.5 2000-12-01
GBGB0029360.5A GB0029360D0 (en) 2000-12-01 2000-12-01 Humanised antibodies and uses thereof

Publications (2)

Publication Number Publication Date
WO2002044217A2 WO2002044217A2 (en) 2002-06-06
WO2002044217A3 true WO2002044217A3 (en) 2002-11-21

Family

ID=9904280

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/005260 WO2002044217A2 (en) 2000-12-01 2001-11-29 Humanised antibodies and uses thereof

Country Status (5)

Country Link
US (1) US20050033030A1 (en)
EP (1) EP1339752A2 (en)
AU (1) AU2002220843A1 (en)
GB (1) GB0029360D0 (en)
WO (1) WO2002044217A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10256900A1 (en) 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumor-specific recognition molecules
DE10303664A1 (en) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Detection molecules for the treatment and detection of tumors
AU2005250432B2 (en) 2004-05-28 2011-09-15 Asuragen, Inc. Methods and compositions involving microRNA
ES2503739T3 (en) 2004-11-12 2014-10-07 Asuragen, Inc. Procedures and compositions involving miRNA and miRNA inhibitor molecules
CA2662226C (en) 2006-09-10 2020-08-04 Glycotope Gmbh Fully human high yield production system for improved antibodies and proteins
AU2007299828C1 (en) * 2006-09-19 2014-07-17 Interpace Diagnostics, Llc MicroRNAs differentially expressed in pancreatic diseases and uses thereof
EP2145001A2 (en) * 2006-09-19 2010-01-20 Asuragen, Inc. Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
EP1920781B1 (en) 2006-11-10 2015-03-04 Glycotope GmbH Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
AU2007333109A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Functions and targets of let-7 micro RNAs
EP2104735A2 (en) * 2006-12-08 2009-09-30 Asuragen, INC. Mir-21 regulated genes and pathways as targets for therapeutic intervention
WO2008073915A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Micrornas differentially expressed in leukemia and uses thereof
US20090175827A1 (en) * 2006-12-29 2009-07-09 Byrom Mike W miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090131354A1 (en) * 2007-05-22 2009-05-21 Bader Andreas G miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
CN101801419A (en) * 2007-06-08 2010-08-11 米尔纳疗法公司 Gene and path as the miR-34 regulation and control for the treatment of the target of intervening
SI2158315T1 (en) 2007-06-25 2016-05-31 Esbatech, An Alcon Biomedical Research Unit Llc Methods of modifying antibodies, and modified antibodies with improved functional properties
EP2198050A1 (en) 2007-09-14 2010-06-23 Asuragen, INC. Micrornas differentially expressed in cervical cancer and uses thereof
US20090186015A1 (en) * 2007-10-18 2009-07-23 Latham Gary J Micrornas differentially expressed in lung diseases and uses thereof
US8071562B2 (en) * 2007-12-01 2011-12-06 Mirna Therapeutics, Inc. MiR-124 regulated genes and pathways as targets for therapeutic intervention
US20090192114A1 (en) * 2007-12-21 2009-07-30 Dmitriy Ovcharenko miR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention
EP2260110B1 (en) * 2008-02-08 2014-11-12 Asuragen, INC. miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
US20090233297A1 (en) * 2008-03-06 2009-09-17 Elizabeth Mambo Microrna markers for recurrence of colorectal cancer
WO2009154835A2 (en) * 2008-03-26 2009-12-23 Asuragen, Inc. Compositions and methods related to mir-16 and therapy of prostate cancer
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
EP2145901B1 (en) 2008-07-18 2012-11-14 Technische Universität Braunschweig Recombinant anti-MUC1 antibodies
WO2010056737A2 (en) * 2008-11-11 2010-05-20 Mirna Therapeutics, Inc. Methods and compositions involving mirnas in cancer stem cells
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
US8287865B2 (en) 2009-09-16 2012-10-16 Immunomedics, Inc. Class I anti-CEA antibodies and uses thereof
WO2013026887A1 (en) 2011-08-22 2013-02-28 Glycotope Gmbh Microorganisms carrying a tumor antigen
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
EP3081576B1 (en) * 2013-12-12 2019-08-21 Shanghai Hengrui Pharmaceutical Co., Ltd. Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
AU2015231256A1 (en) 2014-03-19 2016-09-22 Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
EP3794041B1 (en) 2018-05-18 2023-07-12 Glycotope GmbH Anti-muc1 antibody

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BRADY K ET AL: "RATIONAL MUTAGENESIS OF A RECOMBINANT ANTI-TUMOR ANTIBODY", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. SUPPL. 4, no. 35, September 1999 (1999-09-01), pages S350,AN1416, XP008003949, ISSN: 0959-8049 *
DENTON G ET AL: "Primary sequence determination and molecular modelling of the variable region of an antiMUC1 mucin monoclonal antibody.", EUROPEAN JOURNAL OF CANCER, vol. 31A, no. 2, 1995, pages 214 - 221, XP002207752, ISSN: 0959-8049 *
DENTON GRAEME ET AL: "Production and characterization of an anti-(MUC1 mucin) recombinant diabody.", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 48, no. 1, April 1999 (1999-04-01), pages 29 - 38, XP002207755, ISSN: 0340-7004 *
LAING P ET AL: "SELECTION OF PEPTIDE LIGANDS FOR THE ANTIMUCIN CORE ANTIBODY C595 USING PHAGE DISPLAY TECHNOLOGY: DEFINITION OF CANDIDATE EPITOPES FOR A CANCER VACCINE", JOURNAL OF CLINICAL PATHOLOGY, LONDON, GB, vol. 48, no. 3, 1995, pages M136 - M141, XP000906851, ISSN: 0021-9746 *
LO B: "ENGINEERING THE MAGIC BULLET FOR TARGETED THERAPY IN BLADDER CANCER", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, no. 37, 21 October 2001 (2001-10-21), pages S228, XP008003950, ISSN: 0959-8049 *
PRICE M R ET AL: "C595 - A MONOCLONAL ANTIBODY AGAINST THE PROTEIN CORE OF HUMAN URINARY EPITHELIAL MUCIN COMMONLY EXPRESSED IN BREAST CARCINOMAS", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 61, no. 5, 1990, pages 681 - 686, XP000941253, ISSN: 0007-0920 *
SATO K ET AL: "HUMANIZATION OF A MOUSE ANTI-HUMAN INTERLEUKIN-6 RECEPTOR ANTIBODY COMPARING TWO METHODS FOR SELECTING HUMAN FRAMEWORK REGIONS", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 31, no. 5, 1994, pages 371 - 381, XP001069947, ISSN: 0161-5890 *
SAUL FREDERICK A ET AL: "Structural patterns at residue positions 9, 18, 67 and 82 in the V-H framework regions of human and murine immunoglobulins.", JOURNAL OF MOLECULAR BIOLOGY, vol. 230, no. 1, 1993, pages 15 - 20, XP002207753, ISSN: 0022-2836 *

Also Published As

Publication number Publication date
GB0029360D0 (en) 2001-01-17
WO2002044217A2 (en) 2002-06-06
EP1339752A2 (en) 2003-09-03
US20050033030A1 (en) 2005-02-10
AU2002220843A1 (en) 2002-06-11

Similar Documents

Publication Publication Date Title
WO2002044217A3 (en) Humanised antibodies and uses thereof
WO2005003170A3 (en) Modified antibody fragments
NZ593068A (en) IL-18 antibody
RS51829B (en) Human antibodies specific for interleukin 15 (il-15)
IN2009KN02655A (en)
WO2002090566A3 (en) Recombinant tumor specific antibody and use thereof
EP2322552A3 (en) IL-1beta binding antibodies and fragments thereof
NZ529571A (en) Human antibodies that bind human IL-12 and methods for producing
WO2001053353A3 (en) Recombinant antibodies to human interkleukin-1 beta
RU2602878C3 (en) CONJUGATES "KALYCHEAMICIN DERIVATIVE-CARRIER"
WO2002016436A3 (en) ANTIBODIES TO HUMAN IL-1$g(b)
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
EP2221317A3 (en) PEGylated single domain antibodies (dAb)
WO2003018771A3 (en) A system for antibody expression and assembly
WO2005003169A3 (en) Modified antibody fab fragments
NZ596295A (en) Anti-5T4 antibodies and uses thereof
EP2267034A3 (en) Gold-binding protein and use thereof
WO1998050433A3 (en) Human monoclonal antibodies to epidermal growth factor receptor
SG143018A1 (en) Human monoclonal antibodies to ctla-4
WO2005003171A3 (en) Modified antibody fragments
WO2003068801A3 (en) Antibody variants with faster antigen association rates
WO2004022717A3 (en) Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen
AU628948B2 (en) Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof
WO2005082938A3 (en) Anti-human tenascin monoclonal antibody
WO2002067848A3 (en) PEPTIDES FROM THE 16/6id ANTIBODY FOR TREATING SLE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001998567

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001998567

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10433349

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2001998567

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP